NO20015859L - A- <beta> peptide preparations and methods for their preparation - Google Patents
A- <beta> peptide preparations and methods for their preparationInfo
- Publication number
- NO20015859L NO20015859L NO20015859A NO20015859A NO20015859L NO 20015859 L NO20015859 L NO 20015859L NO 20015859 A NO20015859 A NO 20015859A NO 20015859 A NO20015859 A NO 20015859A NO 20015859 L NO20015859 L NO 20015859L
- Authority
- NO
- Norway
- Prior art keywords
- beta
- preparation
- methods
- peptide preparations
- preparations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13704799P | 1999-06-01 | 1999-06-01 | |
PCT/US2000/015302 WO2000072870A1 (en) | 1999-06-01 | 2000-06-01 | Compositions of a-beta peptide and processes for producing same |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20015859D0 NO20015859D0 (en) | 2001-11-30 |
NO20015859L true NO20015859L (en) | 2002-02-01 |
Family
ID=22475602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20015859A NO20015859L (en) | 1999-06-01 | 2001-11-30 | A- <beta> peptide preparations and methods for their preparation |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1181040A1 (en) |
JP (1) | JP2003519620A (en) |
KR (1) | KR20020016813A (en) |
CN (1) | CN1353615A (en) |
AR (1) | AR024558A1 (en) |
AU (1) | AU5726100A (en) |
BG (1) | BG106249A (en) |
BR (1) | BR0011251A (en) |
CA (1) | CA2374897A1 (en) |
CZ (1) | CZ20014150A3 (en) |
EE (1) | EE200100649A (en) |
HK (1) | HK1045938A1 (en) |
HR (1) | HRP20010901A2 (en) |
IL (1) | IL146575A0 (en) |
IS (1) | IS6182A (en) |
MX (1) | MXPA01012355A (en) |
NO (1) | NO20015859L (en) |
NZ (1) | NZ515744A (en) |
PE (1) | PE20010212A1 (en) |
PL (1) | PL352575A1 (en) |
RU (1) | RU2001135800A (en) |
SK (1) | SK17012001A3 (en) |
TR (1) | TR200103476T2 (en) |
WO (1) | WO2000072870A1 (en) |
ZA (1) | ZA200109704B (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
EP2082749A3 (en) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
AU1225702A (en) * | 2000-09-19 | 2002-04-02 | Evotec Neurosciences Gmbh | Methods and compounds for treating brain amyloidosis |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
PE20050627A1 (en) | 2003-05-30 | 2005-08-10 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE |
SE0401601D0 (en) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
JP2008523815A (en) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | Humanized amyloid beta antibody for use in improving cognition |
KR101667623B1 (en) | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | Monoclonal antibodies against amyloid beta protein and uses thereof |
PL1954718T3 (en) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
CA2630344C (en) | 2006-03-23 | 2015-04-28 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
DK2182983T3 (en) | 2007-07-27 | 2014-07-14 | Janssen Alzheimer Immunotherap | TREATMENT OF AMYLOIDOGENIC DISEASES WITH HUMANIZED ANTI-ABETA ANTIBODIES |
JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
MX336196B (en) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Amyloid-beta binding proteins. |
MX358739B (en) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Amyloid-beta binding proteins. |
GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
SG11201610734RA (en) | 2014-07-10 | 2017-01-27 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
CN114957438B (en) * | 2022-06-28 | 2024-04-02 | 福建亿彤生物科技有限公司 | Human Abeta 1-42 epitope polypeptide for detecting Alzheimer disease and preparation method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0526511B1 (en) * | 1990-04-27 | 1997-05-28 | MCMICHAEL, John | Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2000
- 2000-05-31 PE PE2000000521A patent/PE20010212A1/en not_active Application Discontinuation
- 2000-05-31 AR ARP000102690A patent/AR024558A1/en unknown
- 2000-06-01 CN CN00808374A patent/CN1353615A/en active Pending
- 2000-06-01 AU AU57261/00A patent/AU5726100A/en not_active Abandoned
- 2000-06-01 EP EP00942668A patent/EP1181040A1/en not_active Withdrawn
- 2000-06-01 SK SK1701-2001A patent/SK17012001A3/en unknown
- 2000-06-01 CZ CZ20014150A patent/CZ20014150A3/en unknown
- 2000-06-01 BR BR0011251-8A patent/BR0011251A/en not_active Application Discontinuation
- 2000-06-01 MX MXPA01012355A patent/MXPA01012355A/en unknown
- 2000-06-01 RU RU2001135800/14A patent/RU2001135800A/en unknown
- 2000-06-01 NZ NZ515744A patent/NZ515744A/en unknown
- 2000-06-01 KR KR1020017015474A patent/KR20020016813A/en not_active Application Discontinuation
- 2000-06-01 TR TR2001/03476T patent/TR200103476T2/en unknown
- 2000-06-01 CA CA002374897A patent/CA2374897A1/en not_active Abandoned
- 2000-06-01 PL PL00352575A patent/PL352575A1/en not_active Application Discontinuation
- 2000-06-01 IL IL14657500A patent/IL146575A0/en unknown
- 2000-06-01 JP JP2001511317A patent/JP2003519620A/en not_active Withdrawn
- 2000-06-01 EE EEP200100649A patent/EE200100649A/en unknown
- 2000-06-01 WO PCT/US2000/015302 patent/WO2000072870A1/en not_active Application Discontinuation
-
2001
- 2001-11-26 ZA ZA200109704A patent/ZA200109704B/en unknown
- 2001-11-29 IS IS6182A patent/IS6182A/en unknown
- 2001-11-30 NO NO20015859A patent/NO20015859L/en not_active Application Discontinuation
- 2001-12-04 HR HR20010901A patent/HRP20010901A2/en not_active Application Discontinuation
- 2001-12-20 BG BG106249A patent/BG106249A/en unknown
-
2002
- 2002-08-23 HK HK02106241.2A patent/HK1045938A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU5726100A (en) | 2000-12-18 |
IL146575A0 (en) | 2002-07-25 |
TR200103476T2 (en) | 2002-04-22 |
KR20020016813A (en) | 2002-03-06 |
SK17012001A3 (en) | 2002-06-04 |
PL352575A1 (en) | 2003-08-25 |
AR024558A1 (en) | 2002-10-16 |
NZ515744A (en) | 2004-04-30 |
HK1045938A1 (en) | 2002-12-20 |
PE20010212A1 (en) | 2001-02-22 |
BG106249A (en) | 2002-08-30 |
HRP20010901A2 (en) | 2003-04-30 |
ZA200109704B (en) | 2003-02-26 |
IS6182A (en) | 2001-11-29 |
CA2374897A1 (en) | 2000-12-07 |
CZ20014150A3 (en) | 2002-05-15 |
WO2000072870A1 (en) | 2000-12-07 |
NO20015859D0 (en) | 2001-11-30 |
EP1181040A1 (en) | 2002-02-27 |
CN1353615A (en) | 2002-06-12 |
EE200100649A (en) | 2003-02-17 |
MXPA01012355A (en) | 2003-06-24 |
JP2003519620A (en) | 2003-06-24 |
RU2001135800A (en) | 2003-08-20 |
BR0011251A (en) | 2002-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20015859D0 (en) | Β-beta beta peptide preparations and methods for their preparation | |
NO992779D0 (en) | OB fusion protein preparations and methods for their preparation | |
NO20021401D0 (en) | Conazoline compounds and pharmaceutical preparations containing such compounds | |
IS6040A (en) | Valdekoxib preparations | |
NO20014220D0 (en) | <Kappa-agonist compounds and pharmaceutical preparations thereof | |
IS5953A (en) | Pharmaceutical preparations from microplated eplerenones | |
DK1210113T3 (en) | Combined vaccine preparations | |
EE200200038A (en) | Preserved pharmaceutical preparations | |
NO20016277D0 (en) | Systems and methods for aerolizing pharmaceutical formulations | |
DK0988861T3 (en) | Stabilized protein preparations | |
HUP0300334A3 (en) | Pharmaceutical preparations and their manufacture | |
NO20016247D0 (en) | Streptogramin derivatives, their preparation and preparations containing the derivatives | |
NO20021949L (en) | New hormone preparations and their use | |
AU5744200A (en) | Human transport proteins | |
PT1228039E (en) | N-GUANIDINOALQUILAMIDES ITS PREPARATION ITS USE AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | |
DK1178799T3 (en) | Gastroprotected microgranules, method of obtaining same and pharmaceutical preparations | |
DE69926012D1 (en) | PHARMACEUTICAL PREPARATIONS | |
ATE246494T1 (en) | EFFORTABLE PREPARATIONS | |
AU4483500A (en) | Human membrane-associated proteins | |
DE69906934D1 (en) | PHARMACEUTICAL PREPARATIONS | |
NO20020777L (en) | Pharmaceutical preparations containing derivatives and process for their preparation | |
DK1192163T3 (en) | Dithiepino [6,5-b] pyrines, related preparations and methods | |
DK1183241T3 (en) | Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising these | |
DE50009295D1 (en) | NETWORK-FREE PREPARATIONS | |
FR2802775B1 (en) | ICE AND AEREES PREPARATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |